Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience

References

• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2012;6:991–1030.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.
   PubMed Web of Science ®Google Scholar
• Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:CD000478.
   PubMed Web of Science ®Google Scholar
• Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;10:CD000067.
   Google Scholar
• Gordon M, Taylor K, Akobeng AK, et al. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD010233.
   Google Scholar
• Gong J, Zhu L, Guo Z, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One. 2013;8:e81487.
   PubMed Web of Science ®Google Scholar
• Jess T, Lopez A, Andersson M, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1793–1800.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444–447.
   PubMed Web of Science ®Google Scholar
• Orlando A, Renna S, Rizzuto G, et al. Selective use of combination therapy in patients with infliximab-resistant inflammatory bowel disease: data from a tertiary referral center. Clin Gastroenterol Hepatol. 2016;14:914.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Salleron J, Filippi J, et al. Anti-TNF monotherapy for Crohn's disease: a 13-year multicentre experience. J Crohns Colitis. 2016;10:516–524.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Cottone M, Orlando A. The selective use of combination therapy in patients with inflammatory bowel disease resistant to anti-TNF: to whom, how and how long? J Crohns Colitis. 2016;10:1451.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Choi WY, Park KS, et al. Differences in the adverse effects of azathioprine between inflammatory bowel disease and autoimmune hepatitis in Korean patients. Korean J Gastroenterol. 2014;64:348–355.
   PubMedGoogle Scholar
• Di Salvo A, Fabiano C, Mannara V, et al. Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. Dig Liver Dis. 2016;48:1506–1509.
   PubMedGoogle Scholar
• Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–142.
   PubMed Web of Science ®Google Scholar
• López-Martín C, Chaparro M, Espinosa L, et al. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2011;34:385–392.
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485–489.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:331–342.
   PubMed Web of Science ®Google Scholar
• Costantino G, Furfaro F, Belvedere A, et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6:588–596.
   PubMed Web of Science ®Google Scholar
• Moran GW, Dubeau MF, Kaplan GG, et al. Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol. 2015;21:7795–7804.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404–1410.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Pasternak B, Svanström H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177:1296–1305.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 2013;38:1255–1266.
   PubMed Web of Science ®Google Scholar
• Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.
   PubMed Web of Science ®Google Scholar
• Domenech E, Nos P, Papo M, et al. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol. 2005;40:52–55.
   PubMed Web of Science ®Google Scholar
• Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med. 2011;154:814–823.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025–1030.
   PubMed Web of Science ®Google Scholar
• Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:593–599.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103:1783–1800.
   PubMed Web of Science ®Google Scholar
• Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases – a prospective study on incidence and severity. J Crohns Colitis. 2016;10:61–68.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:654–661.
   PubMed Web of Science ®Google Scholar
• Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6:905–912.
   PubMed Web of Science ®Google Scholar
• Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut. 2014;63:1695–1699.
   PubMed Web of Science ®Google Scholar